Li Xia, Wang Yuan-Bo, Wang Chao-Chen, Li Xin, Hu Yuan
Graduate School, Chinese PLA General Hospital Beijing 100089, China Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital Beijing 100089, China.
Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital Beijing 100089, China.
Zhongguo Zhong Yao Za Zhi. 2022 Nov;47(21):5916-5925. doi: 10.19540/j.cnki.cjcmm.20220613.709.
This study established the EA.hy926 cell myocardial ischemia model to compare the effects of two Kaixin Powder prescriptions, Buxin Decoction(BXD) and Dingzhi Pills(DZP), at three dosages(500, 200, and 100 μg·mL~(-1)) on the cell viability. Further, the public databases(TCMSP, TCMID, SYMMAP, and STRING) and the network pharmacology methods such as KEGG pathway enrichment were employed to decipher the possible molecular mechanism of BXD in exerting the cardioprotective effect. The pharmacological effect of BXD was evaluated with the rat model of isoprenaline(ISO)-induced myocardial ischemia. The expression levels of proteins involved in the phosphatidylinositol-3-kinase/protein kinase B(PI3 K/AKT) signaling pathway were measured by Western blot. BXD significantly increased the viability of EA.hy926 cells, showing the performance superior to DZP. The network pharmacology analysis predicted that BXD might exert cardiac protection through the PI3 K/AKT signaling pathway. The in vivo experiment on rats showed that BXD treatment significantly increased the cardiac ejection fraction(EF), fractional shortening(FS), diastolic left ventricular anterior wall(LVAWd), systolic left ventricular anterior wall(LVAWs), and diastolic left ventricular posterior wall(LVPWd), significantly decreased the beat per minute(BPM) and diastolic left ventricular internal diameter(LVIDd), and significantly improved the ST segment in the electrocardiogram. The pathological results(Masson staining) showed that BXD restored the myocardial thickness, decreased the collagen fiber, increased the muscle fiber, and reduced the infarct area to alleviate myocardial ischemia. Furthermore, BXD lowered the serum levels of inflammatory cytokines [tumor necrosis factor-α(TNF-α) and interleukin-6(IL-6)] and myocardial enzymes [creatine kinase(CK) and lactate dehydrogenase(LDH)], increased the p-AKT/AKT ratio, up-regulated the protein levels of PI3 K, NF-κB, IKK-α, and Bcl-xl, and down-regulated that of the apoptotic protein Bax. In conclusion, BXD may exert cardiac protection effect by regulating the PI3 K/AKT signaling pathway.
本研究建立了EA.hy926细胞心肌缺血模型,以比较两种开心散方剂(补心汤(BXD)和定志丸(DZP))在三种剂量(500、200和100μg·mL⁻¹)下对细胞活力的影响。此外,利用公共数据库(TCMSP、TCMID、SYMMAP和STRING)以及KEGG通路富集等网络药理学方法,来解读BXD发挥心脏保护作用的可能分子机制。采用异丙肾上腺素(ISO)诱导的大鼠心肌缺血模型评估BXD的药理作用。通过蛋白质印迹法检测磷脂酰肌醇-3-激酶/蛋白激酶B(PI3K/AKT)信号通路相关蛋白的表达水平。BXD显著提高了EA.hy926细胞的活力,表现出优于DZP的性能。网络药理学分析预测,BXD可能通过PI3K/AKT信号通路发挥心脏保护作用。对大鼠的体内实验表明,BXD治疗显著提高了心脏射血分数(EF)、缩短分数(FS)、舒张期左心室前壁厚度(LVAWd)、收缩期左心室前壁厚度(LVAWs)和舒张期左心室后壁厚度(LVPWd),显著降低了每分钟心跳次数(BPM)和舒张期左心室内径(LVIDd), 并显著改善了心电图中的ST段。病理结果(Masson染色)显示,BXD恢复了心肌厚度,减少了胶原纤维,增加了肌纤维,并缩小了梗死面积以减轻心肌缺血。此外,BXD降低了血清炎症细胞因子[肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)]和心肌酶[肌酸激酶(CK)和乳酸脱氢酶(LDH)]的水平,提高了p-AKT/AKT比值,上调了PI3K、NF-κB、IKK-α和Bcl-xl的蛋白水平,并下调了凋亡蛋白Bax的水平。总之,BXD可能通过调节PI3K/AKT信号通路发挥心脏保护作用。